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A B S T R A C T
Systemic enzyme therapy has been shown to be efﬁcient in treating pain and inﬂammation associated
with injury or musculoskeletal disorders. However, whether systemic enzyme supplementation also
attenuates subclinical inﬂammation remains to be investigated.
In this randomized controlled trial, we investigated the impact of systemic enzyme supplementation
on inﬂammatory gene expression as well as on markers of inﬂammation in 24 adult men and women
with subclinical inﬂammation (serum C-reactive protein [CRP] levels >1 mg/L and <10 mg/L).
Participants were supplemented with systemic enzymes (Wobenzym1450 FIP from bromelain and
1440 FIP from trypsin, 6 tablets/d) or placebo for periods of 4 weeks separated by a 4-week washout
period.
Systemic enzyme supplementation had no impact on expression levels of whole blood cell
inﬂammatory genes compared with placebo but signiﬁcantly reduced serum IL-6 levels (p = 0.04).
However, there was a signiﬁcant sex  treatment interaction for IL-6 (p = 0.02) and CRP (p = 0.007).
Speciﬁcally, both serum IL-6 and CRP concentrations were signiﬁcantly reduced in men (p  0.03) but not
in women (p  0.08).
This study suggests that short-term supplementation with systemic enzymes may attenuate
subclinical inﬂammation, with perhaps greater effects among men than among women.
ã 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Inﬂammation is being increasingly recognized as a key
etiological factor in the development of atherosclerosis and
subsequent cardiovascular disease (CVD) [1] and is frequently
found co-segregating with obesity and metabolic syndrome [1–3].
C-reactive protein (CRP) has been used extensively as a non-
speciﬁc marker of the acute phase response for decades [4]. Data
have further shown that CRP is a powerful predictor of CVD
outcomes in epidemiological studies [5]. Indeed, studies that have
investigated the predictive value of subclinical CRP levels have
been relatively consistent in showing that individuals with high
serum CRP levels (>3.0 mg/L) are at greater risk of CVD compared to
individuals with lower (<1.0 mg/L) CRP levels, independent of
gender and plasma cholesterol concentrations [6]. Other blood
markers of active subclinical inﬂammation include monocyte* Corresponding author. Tel.: +1 418 656 2131x4355; fax: +1 418 656 5877.
E-mail address: benoit.lamarche@inaf.ulaval.ca (B. Lamarche).
http://dx.doi.org/10.1016/j.phanu.2015.04.004
2213-4344/ã 2015 The Authors. Published by Elsevier B.V. This is an open access article unchemotactic protein (MCP-1), adiponectin and interleukins (IL)
such as IL-6 [7].
Systemic enzyme therapy, which involves the oral delivery of
primarily proteolytic enzymes in combination with rutin and
administered in the absence of food, has been recommended for
many years for the treatment of pain and inﬂammation associated
with musculoskeletal disorders, arthritis and post-surgery [8–10].
However, the impact of systemic enzyme supplementation on
subclinical inﬂammation associated with metabolic syndrome and
obesity is less known. In rabbits fed a lipid-rich, metabolic
syndrome-inducing diet for 8 weeks, supplementation with
systemic enzymes signiﬁcantly reduced serum CRP concentrations
[11]. To the best of our knowledge, no study has yet documented
the impact of systemic enzyme supplementation on subclinical
inﬂammation in humans.
The objective of this study was to examine the impact of
systemic enzyme supplementation on inﬂammatory gene expres-
sion in whole blood cells and on blood markers of inﬂammation in
men and women with subclinical inﬂammation. We hypothesized
that systemic enzyme supplementation for 4 weeks down-
regulates the expression of genes associated with inﬂammationder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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tory biomarkers.
2. Material and methods
2.1. Study design
The study was conducted as a double blind, crossover,
randomized, placebo controlled trial at the Institute of Nutrition
and Functional Foods (INAF) in Québec City, Canada. Participants
were supplemented with systemic enzymes in the form of
Wobenzym1 or placebo for periods of 4 weeks each in random
order, with a 4-week washout between the two treatment phases.
Treatment sequence was assigned to participants via the use of
random sequence of numbers. Allocation to treatment sequence
was concealed by a secure computer-assisted method enabling
preservation of assignments until enrollment was conﬁrmed. The
study sponsor held the trial codes, which were disclosed after
completion of the statistical analyses. Study products
(Wobenzym1 and placebo) were supplied by Mucos Pharma
GmbH & Co. KG (Oberhaching, Bavaria, Germany). The systemic
enzyme product was delivered in tablets each providing 90 mg
(450 FIP units) bromelain from pineapple, 48 mg (1440 FIP units)
trypsin from bovine and porcine pancreas, and 100 mg rutin from
Sophora japonica. The placebo contained no active ingredients.
Both the enzyme product and placebo contained the same inactive
ingredients, were enteric coated, and were white ﬁlm coated to
ensure blinding (titanium dioxide) (Table 1). Participants were
instructed to consume 6 tablets/day, 45 min before a meal for
4 weeks. The study protocol was approved by Université Laval’s
Research Ethics Board and is registered at ClinicalTrial.gov #
NCT01848808.
2.2. Subjects
Men and women were recruited from the general population in
the Québec City metropolitan area through paper advertisements
and electronic newsletters. To be eligible, participants needed to be
aged between 18 and 75 years and have serum CRP levels >1 mg/L
and <10 mg/L on 2 separate days at screening. Exclusion criteria
were: hypersensitivity to components of the systemic enzyme
supplement, severe congenital or acquired coagulation disorders
(e.g. hemophilia, in dialysis patients) or liver damage, pregnancy or
breastfeeding, planned surgical operations during the study, any
clinical signs or laboratory evidence for severe inﬂammatory,
endocrine, renal/pulmonary, neurological, cardiovascular, meta-
bolic, gastrointestinal, hematological, or psychiatric condition and
active malignancy of any type other than basal cell carcinoma.
Other exclusion criteria were current use of anticoagulants or
platelet aggregation inhibitors, chemotherapeutic agents, anti-
biotics, medication for lipids, diabetes, hypertension, inﬂamma-
tion, autoimmune diseases, mood disorders or NSAID within
1 month of entering the study, excessive alcohol consumption
(more than two drinks per day for men, one for women) orTable 1
Composition of study products.
Wobenzym1 Placebo
Active ingredients
Bromelain, mg/tablet 90 0
Trypsin, mg/tablet 48 0
Rutin, mg/tablet 100 0
Other ingredients (binders) Yes Yes
Enteric coating (pH resistant) Yes Yes
White coating (titanium dioxide) Yes Yesalcoholism, smoking, drug use and history of drug abuse, as well as
current use of supplements or natural health products.
A total of 250 subjects were screened by phone and 91 of them
were invited to a ﬁrst screening visit. Forty-one potentially eligible
subjects, based on a ﬁrst serum CRP level of >1 mg/L, were invited
to the 2nd visit to complete the screening process, including a
second assessment of serum CRP. A total of 27 subjects met all
eligibility criteria (10 men and 17 women). One female interrupted
her participation because of adverse event (gastritis). There were
two other dropouts due to lack of availability during the study.
Thus, 24 subjects completed the study (see study ﬂow chart at
Fig. 1).
2.3. Measurements
Subjects were instructed to avoid intense physical exercise 36 h
before blood samples were taken and came to the clinical
investigation unit after a 12 h overnight fast. Inﬂammatory gene
expression in whole blood cells was assessed on samples collected
at the end of each treatment phase. Serum concentrations of
inﬂammatory markers and lipid levels were measured twice on
two consecutive days after each treatment. The mean of the two
post-treatment measurements was used in the analyses. General
health assessment (complete blood count, liver and kidneys
function), blood pressure, anthropometric measurements (height,
weight, waist and hip girths, and body composition) as well as
medical history were assessed prior to randomization. Participants
also completed a questionnaire assessing diet and physical activity,
as well as occurrence of any side effects during the study, as
detailed below.
2.3.1. Anthropometry and blood pressure
Anthropometric measurements (body weight, height, waist and
hip girths) were collected according to standardized procedures
[12] at the ﬁrst screening visit as well as before and after each
phase. Systolic and diastolic blood pressures were averaged from
3 measurements taken after a 10 min rest in the sitting position
using an automated blood pressure monitor (Omron, HEM-907XL).
2.3.2. Body composition assessed with dual-energy X-ray
absorptiometry (DXA)
Baseline body composition was measured prior to initiating the
ﬁrst treatment phase with dual-energy X-ray absorptiometry (GE
Lunar Prodigy Advance, GE Lunar Corporation, Madison, WI, USA).
The scanner was calibrated before each measurement session
against the standard calibration block supplied by the manufac-
turer for possible baseline drift. A quality-control test to monitor
the reproducibility and stability of data was also performed before
each session using a spine phantom provided by the manufacturer.
The value from the quality-control test was plotted on graphs, and
the score of each measurement was required to be within  0.05 g/
cm2 of the baseline result. More detail on the procedure is provided
in Supplementary material.
2.3.3. Diet and physical activity
Eligible subjects received instructions from a registered
dietitian regarding the forbidden use of speciﬁc supplements
and medication during the study and to keep their nutritional and
physical activity habits constant. Dietary intake during the study
was assessed on three occasions using a validated web-based food-
frequency questionnaire (FFQ) [13]: 1- at study entry; 2- after the
ﬁrst treatment and 3- after the second treatment. This validated
FFQ inquires on food intake over the last 4 weeks, which is
consistent with treatment duration in this study. Data from these
questionnaires were analyzed using the Nutrient Data System
software based on a mix of Canadian and FDA-produced nutrient
Fig. 1. Study ﬂow chart.
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Physical Activity Questionnaire (IPAQ) [14], which takes into
account physical activity as a whole (at work, at home,
transportation and leisure). More detail on the procedure is
provided in Supplementary material.
2.3.4. Pro- and anti-inﬂammatory gene expression measurement
PAXgene blood RNA kits (Qiagen, Mississauga, ON, Canada)
were used to isolate mRNA from whole blood cells taken on the last
day of each treatment phase. The concentration of the puriﬁed RNA
was analysed using NanoDrop (Thermo Scientiﬁc, Wilmington, DE,
USA). Complementary DNA (cDNA) synthesis was completed using
1 mg of total RNA and the High Capacity cDNA Kit (Life
Technologies, Foster City, CA, USA). Gene expression was assessed
by real-time PCR (RT-PCR) using Applied Biosystems Gene
Expression Assays. Primers and TaqMan1 probes were obtained
from Applied Biosystems (interleukin-1beta (IL-1b):
Hs01555410_m1, nuclear factor of kappa light polypeptide gene
enhancer in B-cells 1 (NFgB1): Hs00765730_m1, peroxisome
proliferator-activated receptor alpha (PPARA): Hs00947536_m1,
tumor necrosis factor (TNF): Hs00174128_m1, TNF-receptor
associated factor 3 (TRAF3): Hs00936781_m1), Applied Biosys-
tems, Foster City, CA, USA). Each sample was analyzed in triplicate
and calibrated to the ATCB housekeeping gene (Hs99999903_m1).
Relative quantiﬁcation was performed on an Applied Biosystems
7500 Real, Time PCR System and the DDCT calculation method was
used to assess the mean fold expression difference (MFED)
between the two treatments [15].
2.3.5. Pro- and anti-inﬂammatory markers and serum lipids
Serum CRP levels were measured using the Behring Latex-
Enhanced (highly sensitive) CRP assay on the Behring Nephelom-
eter BN-100 (Behring Diagnostic, Westwood, MA) and the
calibrators (N Rheumatology Standards SL) provided by the
manufacturer as described previously [16]. Serum adiponectin
was measured by ELISA (B-Bridge International Inc., #K1001-1).
Serum IL-6 was assessed by immunoassay (R&D system,
#HS600B). Monocyte chemoattractant protein-1 (MCP-1) was
assessed by immunoassay (R&D system, #DCP00). Inter-assaycoefﬁcients of variations (CV) for each of these assays were <1%
(CPR), 5.2% (adiponectin), 7.8% (IL-6) and 5.7% (MCP-1). Serum
cholesterol (C), triglycerides and HDL-C were assessed on a Roche/
Hitachi Modular according to the manufacturer’s speciﬁcations
and using proprietary reagents. Plasma LDL-C concentrations were
calculated using the Friedewald Equation. CVs for cholesterol, LDL-
C, TG and HDL-C were all below 3%.
2.4. Safety and intolerance symptoms
Complete blood count, blood clotting and liver and kidney
functions were assessed after each of the 4-week supplementation
periods. Subjective tolerance ratings of the frequency and intensity
of side effects were obtained by questionnaire administered on site
at the beginning and end of each treatment period. On each
occasion, participants indicated whether each side effect was
absent (0), of mild intensity (1), of moderate intensity (2) or of
severe intensity (3).
2.5. Statistical analyses
Statistical analyses were undertaken in a blinded fashion
without knowledge of treatment allocation. The primary analyses
consisted in comparing the expression levels of anti- and pro-
inﬂammatory genes in whole blood cells between systemic
enzyme supplementation and placebo. The secondary analyses
consisted in assessing the change in the serum inﬂammatory
markers and lipid levels with treatment. Data were analyzed using
the PROC MIXED procedure for repeated measures in SAS (version
9.3; SAS, Inc., Cary, NC). Treatment and sex were considered as
ﬁxed effects and subject was considered as random effect.
Interaction of treatment by sex was investigated systematically
for each study outcome by introducing the appropriate term into
the mixed models. There was no signiﬁcant treatment by sequence
interaction for any of the study outcomes. Variables were log-
transformed if needed prior to statistical analysis. In such cases,
geometric means are presented. Differences have been considered
signiﬁcant at P  0.05 (two-tailed). Analyses were undertaken on a
Table 3
Relative expression of genes related to inﬂammation after supplementation with
systemic enzymes for 4 weeks vs. placebo supplementation.
Gene Systemic enzymes Placebo Fold changea ptx
IL-1b 7.07 (0.14) 7.04 (0.22) 0.98 0.82
NFgB1 6.89 (0.08) 6.83 (0.13) 0.96 0.50
PPAR-a 9.47 (0.09) 9.43 (0.12) 0.97 0.70
TNF 8.60 (0.09) 8.61 (0.12) 1.01 0.92
TRAF3 8.16 (0.08) 8.17 (0.15) 1.01 0.87
Values are presented as means (standard error of the means). Each gene expression
was calibrated to the ATCB housekeeping gene. Higher values indicate lower gene
expression.
Analyses presented there are based on the PROC MIXED procedure in SAS on
N = 24 subjects. P value from the main effect of treatment in the mixed model.
Abbreviations: IL-1b, interleukin-1b; NFgB1, nuclear factor of kappa light
polypeptide gene enhancer in B-cells 1; PPAR-a, peroxisome proliferator-activated
receptor alpha; TNF, tumor necrosis factor; TRAF3, TNF-receptor associated factor 3.
a Fold change in gene expression in the systemic enzymes vs. placebo = 2^-(mean
“delta Ct mean” from the systemic enzymes – mean “delta Ct mean” from the
placebo).
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3. Results
3.1. Subject characteristics at baseline
Table 2shows the baseline characteristics of the 15 women
and 9 men who completed the study. Supplemental Table 1
(Supplementary material) shows their physical activity levels as
well as usual dietary habits. Mean age (S.D.) of participants was
45.5 (17.1) years. Six of the women were postmenopausal. With
respect to ethnicity, 23 subjects were Caucasian and 1 was
Asian. All participants were non-smokers. Mean systolic and
diastolic blood pressures, blood lipids and glucose status were
in the normal range. Average serum CRP concentration at
screening was 2.99 (1.90) mg/L and was slightly higher in
women than in men.
3.2. Systemic enzyme supplementation and inﬂammation
Table 3 summarizes the impact of 4-week systemic enzyme
supplementation vs. placebo on whole blood expression levels of
inﬂammatory genes. There was no difference between treatments
in the expression of any of the selected genes. As shown in Table 4,
4-week supplementation with systemic enzymes vs. placebo
signiﬁcantly reduced serum IL-6 concentrations (p = 0.04) but had
no effect on mean serum CRP (p = 0.47), MCP-1 (p = 0.39) and
adiponectin levels (p = 0.73). A signiﬁcant treatment by sex
interaction was observed for CRP (p = 0.007) as well as for IL-6
(p = 0.02). As shown in Fig. 2, 4-week supplementation with
systemic enzymes compared with placebo signiﬁcantly reduced
serum CRP (p = 0.03) and IL-6 (P = 0.008) in men but not in women
(p  0.08).
3.3. Systemic enzyme supplementation and blood lipids
As shown in Table 5, there was no effect of systemic enzyme
supplementation on lipid levels, with the exception of serum
cholesterol, which was increased slightly but signiﬁcantly by 3.1%
(P = 0.05). Participants’ weight, waist circumference and blood
pressure remained unchanged with treatments (not shown).Table 2
Characteristics of study participants at screening.
Variables All (N = 24) Women
(N = 15)
Men (N = 9)
Age (years) 45.5 (17.1) 44.1 (17.2) 47.8 (17.8)
Body mass index (kg/m2) 26.7 (5.2) 26.2 (6.0) 27.6 (3.8)
Waist circumference (cm) 90.8 (14.4) 86.7 (14.4) 97.8 (12.3)
Percent fat (%) 33.6 (9.3) 36.6 (9.9) 28.6 (5.8)
Total abdominal fat (kg) 2.37 (1.17) 2.23 (1.27) 2.59 (1.00)
Systolic blood pressure
(mmHg)
112.3 (12.9) 107.6 (12.5) 120.1 (9.6)
Diastolic blood pressure
(mmHg)
65.5 (9.3) 63.7 (8.0) 68.4 (10.9)
C-reactive proteina (mg/L) 2.99 (1.90) 3.37 (1.98) 2.36 (1.66)
Fasting glycemia (mmol/L) 5.03 (0.51) 4.91 (0.48) 5.22 (0.54)
Total cholesterol (mmol/L) 5.48 (1.00) 5.62 (0.92) 5.26 (1.15)
LDL-cholesterol (mmol/L) 3.07 (0.82) 3.07 (0.85) 3.07 (0.81)
HDL-cholesterol (mmol/L) 1.76 (0.45) 1.95 (0.44) 1.45 (0.29)
Triglycerides (mmol/L) 1.41 (0.68) 1.30 (0.60) 1.59 (0.81)
Cholesterol\HDL-cholesterol
ratio
3.28 (0.95) 2.99 (0.72) 3.76 (1.12)
Metabolic syndrome (%) 12.5 0 33.3
Values are presented as means (S.D.) except for metabolic syndrome prevalence.
a Average of 2 measurements taken on 2 different occasions.3.4. Compliance and side effects
Compliance as assessed by number of tablets returned to the
research team was very high (95%) and was comparable between
the two treatments (not shown). There was no difference between
the two treatments on safety parameters assessed (liver and
kidney functions, Supplemental Table 2). There was no difference
between treatments in number of red cells, white cells and
platelets. There was a signiﬁcant reduction in the absolute count of
lymphocytes after systemic enzyme supplementation (P = 0.03)
while the relative count of lymphocytes remained unchanged
(P = 0.07, Supplemental Table 3). Occurrence of side effects was low
and similar between the two treatments, with the exception of
fatigue intensity rating and frequency, which was slightly higher
during systemic enzyme supplementation than during placebo
(p = 0.04 both for intensity and frequency, not shown).
4. Discussion
Several studies on inﬂammation related to arthritis and post-
surgery have reported beneﬁcial anti-inﬂammatory effects of
supplementation with systemic enzymes. Less is known about this
treatment modality on subclinical inﬂammation associated with
obesity and metabolic syndrome. Our hypothesis was that
supplementation with systemic enzymes attenuates inﬂammation
in men and women with subclinical inﬂammation and that this
effect can be perceived at the gene expression level as well as at theTable 4
Serum levels of inﬂammatory markers after supplementation with systemic







CRP (mg/L)b 2.17 (2.45) 2.16 (2.13) 0.5% 0.47
IL-6 (pg/mL) 1.25 (0.89) 1.41 (0.98) 11.3% 0.04
MCP-1/CCL2 (pg/mL) 367.6 (113.1) 356.3 (100.7) 3.1% 0.39
Adiponectin (mg/mL)b 8.43 (1.53) 8.53 (1.50) 1.2% 0.73
Values are presented as means (S.D.) and percentage of change from placebo.
Analyses presented there are based on the PROC MIXED procedure in SAS on
N = 24 subjects.
Abbreviations: CRP, C-reactive protein; IL-6, interleukine-6; MCP-1/CCL2, monocyte
chemotactic protein.
a P value from the main effect of treatment in the mixed model. Models for CRP
and IL-6 included treatment, sex and treatment by sex interaction; Model for MCP-
1/CCL2 included treatment only; model for adiponectin included treatment and sex.
b Analyses performed on log-transformed values. Geometric means are
presented in such cases.
Fig. 2. Serum CRP and IL-6 levels in women and men after a 4-week
supplementation with systemic enzymes (black bars &) or placebo (open bars
&). Values are presented as means (standard error of the means).
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supplementation with a mix of systemic enzymes (Wobenzym1)
for 4 weeks has no effect on expression levels of genes related to
inﬂammation in whole blood cells. However, systemic enzyme
supplementation may have subclinical anti-inﬂammatory effects,
as evidenced by a reduction in serum IL-6 concentrations.
Although our study was not originally designed speciﬁcally to
investigate differences between men and women, data revealed a
signiﬁcant treatment by sex interaction for IL-6 and CRP
concentrations. Speciﬁcally, reduction in both of these inﬂamma-
tory markers was signiﬁcant in men but not in women.
While previous studies having investigated systemic enzymes
in acute inﬂammatory conditions have shown similar anti-Table 5








Total cholesterol (mmol/L) 5.61 (0.98) 5.44 (1.03) 3.1% 0.05
LDL-C (mmol/L) 3.22 (0.74) 3.11 (0.77) 3.6% 0.17
HDL-C (mmol/L) 1.74 (0.45) 1.71 (0.48) 1.2% 0.40
Triglycerides (mmol/L)b 1.28 (1.55) 1.21 (1.59) 5.5% 0.20
Total cholesterol:HDL-C
ratio
3.40 (0.93) 3.37 (1.00) 0.9% 0.72
Values are presented as means (S.D.) unless stated otherwise. Analyses presented
there are based on the PROC MIXED procedure in SAS on N = 24 subjects.
Abbreviation: C, cholesterol.
a P value from the main effect of treatment in the mixed model. Models included
treatment only.
b Analyses performed on log-transformed values. Geometric means are
presented.inﬂammatory effects in both men and women [8,17], other
evidence have highlighted sex differences in inﬂammation
processes and levels [18–20]. Sex differences in CRP concentrations
may be due at least partly to the impact of estrogens as
premenopausal women have higher levels of CRP compared to
men [18] and hormone replacement therapy has also been
associated with increased CRP concentrations [21,22]. Data from
our sample are compatible with this concept that women tend to
have higher serum CRP levels than men (+42% higher CRP in
women compared with men). Recent evidence has also suggested
that both gene expression and inﬂammatory biomarkers may
respond differently to dietary change [23,24]. Further studies are
therefore needed in a context of subclinical inﬂammation to
validate the observation that men may be more responsive than
women to certain anti-inﬂammatory therapies, such as systemic
enzyme supplementation.
The apparent disconnect between the absence of change in
inﬂammatory gene expression and the change in inﬂammatory
marker levels in men also needs to be discussed. Changes in gene
expression induced by a dietary intervention generally occur
rapidly, before changes in protein level can be observed. However,
protein levels reﬂect the balance between both RNA and protein
production and turnover. In that context, the correlation between
the concentrations of proteins with their corresponding mRNAs is
not always strong [25]. In the present study, systemic enzymes
were supplemented for a period of 4 weeks, which should have
been long enough to induce changes in gene expression levels,
especially considering that small but signiﬁcant anti-inﬂammatory
effects were observed. It is possible that the effect of systemic
enzymes on gene expression occurred acutely, i.e. after each
supplementation of the tablets, and that it was not perceived when
gene expression levels were measured at the end of the treatment
period. It is also likely that the potential anti-inﬂammatory effect
of systemic enzyme supplementation was not mediated by the
particular genes and transcription factors investigated in this
study, or that whole blood cells do not reﬂect the anti-
inﬂammatory changes occurring in other tissues after supplemen-
tation with systemic enzymes.
Mechanisms through which systemic enzyme products such as
Wobenzym1 may have anti-inﬂammatory effects have been
proposed [11,26,27]. Talaieva and Bratus speculated that systemic
enzymes may act indirectly through reduction of inﬂammation-
associated reactive oxygen species generation, and/or through the
effect of other products in the formulation such as rutin, a
ﬂavonoid with antioxidant properties [28]. Others have suggested
that these proteases may form complexes with cytokines through
the interaction of speciﬁc anti-proteases widely available in human
blood and promote their clearance from inﬂamed tissues via
endocytotic and phagocytic routes [29,30]. Other mechanisms,
such as interactions with cell surface receptors and signal
transduction events have been suggested [29]. One of the systemic
enzyme ingredients, bromelain, has been shown to have anti-
inﬂammatory effects as evidenced by an attenuated IL-1b, IL-6 and
TNF-a from THP-1 cells after LPS stimulation [31].
At the beginning and at the end of each treatment period,
participants were invited to indicate the frequency and intensity of
side effects over the last 4 weeks. Participants reported slightly but
signiﬁcantly more fatigue while being supplemented with
systemic enzyme than placebo both for intensity and frequency.
However, there was no difference in the frequency of other side
effects between systemic enzyme supplementation and placebo.
There was also no difference between the two treatments on safety
parameters of liver and kidney function. The reduction in the
absolute count of lymphocytes observed with the systemic enzyme
treatment was signiﬁcant but remained in the normal range.
Moreover, the absolute count was not different and the white cells,
88 M.-E. Paradis et al. / PharmaNutrition 3 (2015) 83–88platelets and hemoglobin counts remained similar. This is
consistent with previous data and a long history of use having
established that systemic enzymes such as Wobenzym1 are
considered safe.
This study has strengths and limitations. The crossover
randomized double-blind design of this study is a major strength.
Statistics were also performed in a blinded fashion, reducing the
risk of biases. Markers of inﬂammation were measured twice at
screening and after each treatment phase, which contributed to
reduce intra-individual variability and hence increased statistical
power. Compliance was very high (>95%), with only one
participant with a compliance below 80% (79.8%). The number
of subjects who completed the study was high (24/27). This is to
the best of our knowledge the ﬁrst study to have documented the
side effects and the safety of a chronic use (4 weeks) of systemic
enzymes in healthy volunteers with subclinical inﬂammation. On
the other hand, the sample size was limited and not speciﬁcally
calculated to investigate potential treatment by sex interaction in
the response to treatment. The study design did not allow us to
investigate the impact of systemic enzyme supplementation on
inﬂammation in an acute setting, i.e. immediately after ingestion
of the supplement.
In conclusion, data from this study suggest for the ﬁrst time that
short-term supplementation with systemic enzymes may attenu-
ate inﬂammatory processes in healthy individuals with subclinical
inﬂammation, and that this effect may be more important in men
than in women. This apparent difference in inﬂammatory
responses to systemic enzyme supplementation between men
and women needs to be further assessed in future studies.
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